Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Sickle Cell Disease

Clinical and regulatory intelligence for Sickle Cell Disease with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
1
Assets
4

Relevant assets

Gerofit →
NIDDK →
Nigeria →
VAS-101 →

Relevant companies

No related entities indexed yet.

Recent signals(4)

ClinicalJuly 26, 2026

Blood Sampling Study for Sickle Cell Disease Research Initiated by NIDDK

A study has been launched to collect blood samples from individuals with unique red blood cell features related to sickle cell disease.

ClinicalJuly 21, 2026

Phase 1 Trial of VAS-101 Gel for Improved Curcumin Absorption in Sickle Cell Disease

A clinical trial is underway to evaluate the efficacy of VAS-101, a skin gel containing curcumin, in patients with stable sickle cell disease.

StrategyJuly 8, 2026

Study to Enhance Hydroxyurea Adoption for Sickle Cell Disease in Nigeria

A study aims to improve hydroxyurea adoption for sickle cell disease in Nigeria, addressing significant provider-level barriers.

ClinicalJuly 6, 2026

Gerofit Exercise Intervention Study for Sickle Cell Disease Shows Promise

The SICKLE-FIT study aims to evaluate a personalized exercise program for older adults with sickle cell disease.

Upcoming catalysts(1)

PDUFA Date

Vertex Pharmaceuticals — Casgevy

First CRISPR-based therapy PDUFA sets precedent for gene-editing commercialization timelines.

June 20, 2026 · NDA/BLA

Therapeutic areas

Hematology →
Sickle Cell Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.